Recently, Salubris received the Notice on Clinical Trial Approval issued by the National Medical Products Administration, and the clinical trial was agreed to start.
SAL0114 Tablet is a compound independently developed bySalubris, potential candidate for the treatment of clinical depression.
Clinical depression is a common mental disease. The studies showthat the prevalence of depressive disorder is up to 2.1%① in China; the life-time prevalence of depressive disorder inChinese adults is 6.8%②, and thepatients with depressive disorder have low utilization of hygiene services andrarely obtain sufficient treatment. Most of the currently marketedanti-depressants takes severe weeks to take effect, and the clinical demand isunmet. With the improvement of living standards and the public’s enhancedawareness of mental health, the anti-depressant market is expected to becontinuously expanded. Successful R&D and approval for marketing of SAL0114Tablet will further meet the potential clinical demand and provide the patientswith more treatment options.
①Data source: News Conference of the Information Office of The State Council onthe Report on Nutrition and Chronic Diseases of Chinese Residents (2020)
②Data source: Academic Sharing | Study on Epidemiology of Depressive DisorderTreatment in China
